Valuation
- Market cap
- 0
- Revenue TTM
- $14,240,000
- Net income TTM
- $-7,610,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -53.44%
- Debt to equity
- 0.00
Trading
- Volume
- 200
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 50%
- Beta
- -36.74
- Analysts
- —
- Price target
- $1.50
Company profile
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy Sy...
Show more
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. The company was founded in 1991 and is based in Minneapolis, Minnesota.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 763 475 1400
- Website
- https://urologix.com
- Address
- 14405 21st Avenue North, Suite 110, Minneapolis, United States
Latest news
No headlines yet.
